ESCMID 2026 highlights
COBRA Trial – One day is enough
Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days.
Bottom line: Antibiotic durations can safely be much shorter once source control is achieved.
#IDSky
clarityinitiative.org/escmid-2026-...
Potential harm seemed to be even higher among specific subgroups, including immunocompromised hosts! 😳
#IDsky #TxID #IDOnc #PulmSky #ICUsky
www.remapcap.org/oseltamivir-...
REMAP-CAP domain on oseltamivir vs no-antiviral for patients admitted at ICU with influenza is stopped due to potential harm!
90d mortality:
Oseltamivir=19.4% (62/319)
No antiviral=13.7% (17/124)
Last word for oseltamvir?
What’s the rationale for harm? #IDSky
www.remapcap.org/oseltamivir-...
Excited to share an article that I've long awaited to share seeking to answer: What is the right dose of cephalexin/cefadroxil for SSTIs?
We reviewed clinical studies & conducted PTA sims to elucidate this #IDSky @absteward.bsky.social
accpjournals.onlinelibrary.wiley.com/doi/10.1002/...
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://nej.md/4nWaxvM
#ASCO26
clarityinitiative.org
Clinical Literature Appraisal and Research education in InfecTious diseases
Optimal cephalexin and cefadroxil dosing for skin and soft tissue infections (SSTIs) is unclear. We summarize clinical and pharmacokinetic/pharmacodynamic (PK/PD) data that compare dosing strategies ...
accpjournals.onlinelibrary.wiley.com
There’s enough evidence from observational and RCT subgroups to stop excluding systematically immunocompromised hosts from duration trials.
Uncomplicated source + early response should always mean shorter.
1 in 3 patients in @shorten2trial.bsky.social is inmunocompromised
bsky.app/profile/jose...
SHORTEN2 results have been presented at #CongresoSEIMC2026!
7-day treatments were shown superior to 14-day in reducing antibiotic exposure and adverse events while maintaining efficacy.
Fantastic work by >100 researchers across 37 Spanish hospitals! #TeamPride #IDsky #AMSsky @seimc.bsky.social
José Molina
José Molina
Jonathan Ryder, MD
NEJM.org
Steven Tong
Cefepime/Zidebactam:
Class: DBO Inhibitor + 4th-Gen Cephalosporin
Potent PBP2 “Enhancer Effect".
Broad serine beta-lactamases and complementary PBP binding against MBLs
Demonstrated success in compassionate-use salvage therapy for extensively drug-resistant, NDM-producing P. aeruginosa #idsky
Amazing 😍
🔥SHORTEN 2 RCT
A 7-day treatment course is superior to 14 days for uncomplicated Pseudomonas aeruginosa bacteremia, achieving similar clinical response rates with lower antibiotic exposure, fewer superinfections, and fewer serious adverse events #idsky
@shorten2trial.bsky.social
We’re happy to share that results of the @shorten2trial.bsky.social will be presented at the #XXIXCongresoSEIMC!
📆 Friday, May 29 - 14:25h
📍Room 0D
📻 Stay tuned! #AMSsky #IDSky @absteward.bsky.social @idstewardship.bsky.social @bradspellberg.bsky.social @drtoddlee.bsky.social @esgap.bsky.social
#ShorterIsBetter in immunocompromised hosts?
Short treatments are feasible in early responders without source control issues.
A significant number of observational studies serve as proof-of-concept on the feasibility of short courses in selected patients (see ⚠️)
#AMSsky #IDOnc #TxID #IDsky
SHORTEN-2 trial
SHORTEN-2 trial
SHORTEN-2 trial
José Molina
Antibiotic Steward 🅱️C🆔🅿️🌟
Antibiotic Steward 🅱️C🆔🅿️🌟
🔥FDA has approved Zaynich (cefepime and zidebactam) for adults with complicated urinary tract infections (cUTIs) caused by designated susceptible microorganisms.🔥 www.accessdata.fda.gov/drugsatfda_d...
